Prevention of vein graft failure: Potential applications for gene therapy

Cardiovascular Research

Volumn 35, Issue 3, 1997, Pages 442-450

  Baker, Andrew H ^a   Mehta, Dheeraj ^a   George, Sarah J ^a   Angelini, Gianni D ^a  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

Adenovirus; Endothelium; Gene therapy; Smooth muscle cells; Vein graft

Indexed keywords

ANGINA PECTORIS; ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; GENE TARGETING; GENE THERAPY; GRAFT FAILURE; GRAFT OCCLUSION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE FIBER; SWINE; TRANSGENE; VASCULAR ENDOTHELIUM; VEIN GRAFT;

GENE THERAPY; GENE TRANSFER TECHNIQUES; GRAFT OCCLUSION, VASCULAR; HUMANS; MODELS, BIOLOGICAL; ORGAN CULTURE TECHNIQUES; RESEARCH;

EID: 0030730988     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(97)00116-8     Document Type: Review

References (74)

1. Marwick C Coronary bypass grafting: economics, including rehabilitation. Curr Opin Cardiol. 9:1994;635-640.
2. Izzat M, West R, Bryan A Coronary artery bypass surgery: current practice in the United Kingdom. Br Heart J. 71:1994;382-385.
3. Barner H New arterial conduits for coronary bypass surgery. Semin Thorac Cardiovasc Surg. 6:1994;76-80.
4. Campeau L, Enjalbert M, Lesperance Jet al. Atherosclerosis and late closure of aortocoronary saphenous vein grafts: sequential angiographic studies at 2 weeks, 1 year, 5 to 7 years and 10 to 12 years after surgery. Circulation. 68(II):1983;1s-7s.
5. Cox J, Chiasson D, Gotlieb A Stranger in a strange land: the pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries. Prog Cardiovasc Dis. 34:1991;45-68.
6. Fuster V, Chesebro J Aortocoronsry artery vein graft disease: experimental and clinical approach for the understanding of the role of platelets and platelet inhibitors. Circulation. 72(V):1985;65s-70s.
7. Bryan A, Angelini G The biology of saphenous vein graft occlusion: etiology and strategies for prevention. Curr Opin Cardiol. 9:1994;641-649.
8. Davies M, Hagen P-O Pathobiology of intimal hyperplasia: a review. Eur J Vasc Surg. 9:1995;7-18.
9. Ross R The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362:1993;801-809.
10. Jeremy J, Jackson C, Bryan A, Angelini G Eicosanoids, fatty acids and restenosis following coronary artery bypass graft surgery and balloon angioplasty. Prostagl Leukotr Essential Fatty Acids. 54:1996;385-402.
11. O'Brien E, deBlois D, Schwartz S. A critical examination of animal models of restenosis following angioplasty. In: Dobrin P, ed. Intimal Hyperplasia. Austin: RG Landes Company, 1994:229-256.
12. Gryglewski R, Chlopicki Swies J, Niezabitowski P Prostacyclin, nitric oxide and atherosclerosis. Ann NY Acad Sci USA. 748:1995;194-207.
13. Underwood M, More R, Weeraseena Net al. The effect of surgical preparation and in vitro distension on the intrinsic fibrinolytic activity of human saphenous vein. Eur J Vasc Surg. 7:1993;518-522.
14. Dobrin P. Mechanical factors associated with the development of intimal hyperplasia with respect to vascular grafts. In: Dobrin P, ed. Intimal Hyperplasia. Austin: RG Landes Company, 1994:85-109.
15. Sterpetti A, Cucina A, Fragale Aet al. Shear stress influences the release of platelet-derived growth factor and basic fibroblast growth factor by arterial smooth muscle cells. Eur J Vasc Surg. 8:1994;138-142.
16. Jeremy J, Dashwood D, Izzat M, Mehta D, Bryan A, Angelini G. Nitric oxide synthase, and cyclic nucleotide formationin porcine vein grafts. Ann Thorac Surg 1996;(in press).
17. Ohara Y, Peterson TE, Harrison DG Hypercholesterolaemia increases endothelial superoxide anion production. J Clin Invest. 91:1993;2546-2551.
18. Carlos T, Harlan J Membrane proteins involved on phagocyte adherence to endothelium. Immunol Rev. 114:1990;5-28.
19. Newby A, George S Proposed roles for growth factors in mediating smooth muscle cell proliferation in vascular pathologies. Cardiovasc Res. 27:1993;1173-1183.
20. Schwartz S, deBois D, O'Brien E The intima. Soil for atherosclerosis and restenosis. Circ Res. 77:1995;445-465.
21. Francis S, Hunter S, Holt Cet al. Release of platelet-derived growth factor activity from pig venous arterial grafts. J Thorac Cardiovasc Surg. 108:1994;540-548.
22. George S, Fabunmi R, Williams A, Newby A An essential role for platelet derived growth factor in neointima formation in human saphenous vein in vitro. Atherosclerosis. 120:1996;227-240.
23. Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res. 75:1994;539-545.
24. Zempo N, Kenagy RD, Au Tet al. Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid. J Vasc Surg. 20:1994;209-217.
25. Southgate K, Fisher M, Banning Aet al. Upregulation of basement membrane degrading metalloproteinase secretion after balloon injury of pig carotid arteries. Circ Res. 79:1996;1177-1187.
26. George SJ, Zaltsman AB, Newby AC Surgical preparative injury and neointima formation increase MMP-9 expression and MMP-2 activation in human saphenous vein. Cardiovasc Res. 33:1997;447-459.
27. Southgate K, Izzat M, Knight D, Angelini G. Up regulation of basement membrane degrading gelatinases in pig saphenous vein grafts. Br Heart J 1995;73 (suppl 3):46.
28. Soyombo AA, Angelini G, Bryan A, Jasani B, Newby AC Intimal proliferation in an organ culture of human saphenous vien. Am J Path. 137:1990;1401-1414.
29. Angelini GD, Soyombo AA, Newby AC Smooth muscle cell proliferation in response to injury in an organ culture of human saphenous vein. Eur J Vasc Surg. 5:1991;5-12.
30. Soyombo A, Angelini G, Newby A Neointima formation is promoted by surgical preparation and inhibited by cyclic nucleotides in human saphenous vein organ cultures. J Thorac Cardiovasc Surg. 109:1995;2-12.
31. Soyombo AA, Angelini GD, Bryan AJ, Newby AC Surgical preparation induces injury and promotes smooth muscle cell proliferation in a culture of human saphenous vein. Cardiovasc Res. 27:1993;1961-1967.
32. Kranshofer A, Baker A, Newby A Expression of tissue inhibitors of metalloproteinases (TIMPs) in huma saphenous-vein. Heart. 75:1996;159A.
33. Mehta D, Angelini G, Bryan A Experimental models of accelerated atherosclerosis syndromes. Int J Cardiol. 56:1996;235-257.
34. Angelini G, Bryan A, Williams H, Morgan R, Newby A Distension promotes platelet and leukocyte adhesion and reduces short-term patency in pig arteriovenous bypass grafts. J Thorac Cardiovasc Surg. 99:1990;433-439.
35. Angelini G, Bryan A, Williams Het al. Time-course of medial and intimal thickening in pig venous arterial grafts: relationship to endothelial injury and cholesterol accumulation. J Thorac Cardiovasc Surg. 103:1992;1093-1103.
36. Chen SJ, Wilson JM, Muller DWM Adenovirus-mediated gene transfer of soluble vascular cell adhesion molecule to porcine interposition vein grafts. Circulation. 89:1994;1922-1928.
37. Kupfer J, Ruan X, Liu G, Matloff J, Forrester J, Chaux A High-efficiency gene transfer to autologous rabbit jugular vein grafts using adenovirus-transferrin/polylysine-DNA complexes. Human Gene Therapy. 5:1994;1437-1443.
38. Schneider MD, French BA The advent of adenovirus: gene therapy for cardiovascular disease. Circulation. 88(4 Part 1):1993;1937-1942.
39. Lemarchand P, Jones M, Yamada I, Crystal RG In vivo gene transfer and expression in normal uninjured blood vessels using replication-deficient recombinant adenovirus vectors. Circ Res. 72:1993;1132-1138.
40. Schulick AH, Dong G, Newman KD, Virmani R, Dichek DA Endothelium-specific in vivo gene transfer. Circ Res. 77:1995;475-485.
41. Merrick AF, Shewring LD, Sawyer GJ, Gustafsson KT, Fabre JW Comparison of adenovirus gene transfer to vascular endothelial cells in cell culture, organ culture, and in vivo. Transplantation. 62:1996;1085-1089.
42. Wickham TJ, Mathias P, Cheresh D, Nemerow GR Integrins a vb3 and avb5 promote adenovirus internalization but not virus attachment. Cell. 73:1993;309-319.
43. Bett A, Prevec L, Graham F Packaging capacity and stability of human denovirus type 5 vectors. J Virol. 67(10):1993;5911-5921.
44. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci. 91:1994;4407-4411.
45. Zsengeller ZK, Wert SE, Hull WMet al. Persistence of replication-deficient adenovirus-mediated gene transfer in lungs of immune-deficient (nu/nu) mice. Human Gene Therapy. 6:1995;457-467.
46. Yang Y, Trinchieri G, Wilson JM Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nature Med. 1(9):1995;890-893.
47. Tripathy SK, Black HB, Goldwasser E, Leiden JM Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nature Med. 2(5):1996;545-550.
48. Engelhard JF, Ye X, Doranz B, Wilson JM Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci. 91:1994;6196-6200.
49. Engelhardt JF, Litzky L, Wilson JM Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2. Human Gene Therapy. 5:1994;1217-1229.
50. Krougliak V, Graham F Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants. Human Gene Therapy. 6:1995;1575-1586.
51. Yeh P, Dedieu J-F, Orsini C, Vigne E, Denefle P, Perricaudet M Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit. J Virol. 70(1):1996;559-565.
52. Armentano D, Sookdeo CC, Hehir KMet al. Characterization of an adenovirus gene transfer vector containing an E4 deletion. Human Gene Therapy. 6:1995;1343-1353.
53. Gao G-P, Yang Y, Wilson JM Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol. 70(12):1996;8934-8943.
54. Dobner T, Horikoshi N, Rubenwolf S, Shenk T Blockage by adenovirus E4ORF6 of transcriptional activation by the P53 tumor-suppressor. Science. 272:1996;1470-1473.
55. Kochanek S, Clemens PR, Mitani Ket al. A new adenoviral vector: replacement of all viral coding sequences with 28kb of DNA independently expressing both full-length dystrophin and b-galactosidase. Proc Natl Acad Sci. 93:1996;5731-5736.
56. Fisher KJ, Choi H, Burda J, Chen S-J, Wilson JM Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology. 217:1996;11-22.
57. Parks RJ, Chen L, Anton Met al. A helper-dependent adenovirus vector system: removal of helper virus by cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci. 93:1996;13565-13570.
58. Cashin-Hemphill L, Mack W, Pogoda Jet al. Beneficial effects of colestipol plus niacin on coronary atherosclerosis: a 4 year follow up. JAMA. 264:1992;3013-3017.
59. Feldman L, Tahlil O, Steg G Perspectives of arterial gene therapy for the prevention of restenosis. Cardiovasc Res. 32:1996;194-207.
60. O'Brien E, Alpers C, Stewart Det al. Proliferation in primary and restenotic coronary atherectomy tissue: implications for antiproliferative therapy. Circ Res. 73:1993;223-231.
61. Lafont A, Guzman L, Whitlow Pet al. Restenosis after experimental angioplasty. Intimal, medial, and adventitial changes associated with constrictive remodelling. Circ Res. 76:1995;996-1002.
62. Borrelli E, Heyman E, Hsi M, Evans R Targeting of an inducible toxic phenotype in animal cells. Proc Natl Acad Sci USA. 85:1988;7572-7576.
63. Guzman R, Hirscowitz E, Brody Set al. In vivo suppression of injury-induced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase. Proc Natl Acad Sci USA. 91:1994;10732-10736.
64. Ohno T, Gordon D, San Het al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science. 265:1994;781-785.
65. Elashami AA, Saavedra A, Zhang Het al. Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Therapy. 3:1996;85-92.
66. Chang M, Barr E, Seltzer Jet al. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science. 267:1995;518-522.
67. Indolfi C, Avvedimento E, Rapacciuolo Aet al. Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nature Med. 1(6):1995;541-545.
68. Yang Z-Y, Simari RD, Perkins NDet al. Role of the p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury. Proc Natl Acad Sci. 93:1996;7905-7910.
69. von der Leyden HE, Gibbons GH, Morishita Ret al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA. 92:1995;1137-1141.
70. Tzeng E, Shears LL, Robbins PDet al. Vascular gene transfer of the human inducible nitric oxide synthase: characterisation of activity and effects on myointimal hyperplasia. Mol Med. 2:1996;211-225.
71. Baker AH, Wilkinson GWG, Hembry RM, Murphy G, Newby AC Development of recombinant adenoviruses that drive high level expression of the human metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 genes: characterization of their infection into rabbit smooth muscle cells and human MCF-7 adenocarcinoma cells. Matrix Biol. 15:1996;383-395.
72. Forough R, Koyama N, Hasenstab Det al. Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. Circ Res. 79:1996;812-820.
73. Asahara T, Chen D, Tsurumi Yet al. Accelerated restitution of endothelial integrity and endothelium-dependent function after phVEGF(165) gene transfer. Circulation. 94:1996;3291-3302.
74. Zoldhelyi P, McNatt J, Xu X-Met al. Prevention of arterial thrombosis by adenovirus-mediated transfer of cyclooxygenase gene. Circulation. 93:1996;10-17.